ReadyGo Diagnostics Ltd. and Gemina Laboratories Ltd. have achieved a significant milestone in their collaboration, with the successful demonstration of the feasibility of utilising saliva as sample for the detection of Mycobacterium tuberculosis (MTB) through a molecular diagnostic test.
The partnership, begun in January 2023, is aiming to develop a saliva-based test for MTB, which, if successful, would be a breakthrough product with a profound impact on the eradication efforts of TB, particularly in countries like India and Indonesia.
MTB is a highly contagious airborne disease, with an estimated 4 million infections (40% of all cases) remaining undiagnosed and untreated. Diagnosis in low- to middle-income countries, where MTB is most prevalent, often relies on smear microscopy using sputum samples, which has its limitations. The World Health Organization (WHO) has recommended the use of molecular diagnostic tests that can utilize alternative sample types like saliva, thereby improving testing accessibility.
ReadyGo and Gemina are now set to proceed to full product development, leveraging the Geo platform. Geo is a low-cost fluorescence device that can deliver sophisticated molecular diagnostics at a very low price point outside of the laboratory. The objective is to launch an MTB Screening Test in 2024, which can replace smear microscopy with a simple saliva sample. This innovative solution will provide results within 30 minutes, making it accessible and affordable.
Ben Cobb, CEO of ReadyGo Diagnostics, commented: “I’m thrilled about our continued progress and partnership with Gemina to establish a tuberculosis diagnostic platform that can use saliva as the primary sample. We understand the pressing need for a triaging test that that can replace smear microscopy at an affordable price point, particularly in resource-constrained settings.”
Brian Firth, CEO of Gemina, added: “I’m delighted to be seeing such significant results so quickly from our partnership with ReadyGo Diagnostics. Our goal is to create better diagnostic tests for managing patients with tuberculosis, the fact that we have proven feasibility of detecting TB in saliva opens the door to a fundamental improvement in human health and a significant contribution to eradicating TB worldwide.”
ReadyGo Diagnostics Ltd. and Gemina Laboratories Ltd. have announced a major breakthrough in their collaboration, with the successful demonstration of the feasibility of utilising saliva as sample for the detection of Mycobacterium tuberculosis (MTB) through a molecular diagnostic test.
The partnership, initiated in January 2023, is aiming to create a saliva-based test for MTB, which could have a profound impact on the eradication efforts of TB, particularly in countries like India and Indonesia.
MTB is a highly contagious airborne disease, with an estimated 4 million infections (40% of all cases) remaining undiagnosed and untreated. Diagnosis in low- to middle-income countries, where MTB is most prevalent, often relies on smear microscopy using sputum samples, which has its limitations. The World Health Organization (WHO) has recommended the use of molecular diagnostic tests that can utilize alternative sample types like saliva, thereby improving testing accessibility.
ReadyGo and Gemina are now set to proceed to full product development, leveraging the Geo platform. Geo is a low-cost fluorescence device that can deliver sophisticated molecular diagnostics at a very low price point outside of the laboratory. The objective is to launch an MTB Screening Test in 2024, which can replace smear microscopy with a simple saliva sample. This innovative solution will provide results within 30 minutes, making it accessible and affordable.
Ben Cobb, CEO of ReadyGo Diagnostics, stated: “I’m thrilled about our continued progress and partnership with Gemina to establish a tuberculosis diagnostic platform that can use saliva as the primary sample. We understand the pressing need for a triaging test that that can replace smear microscopy at an affordable price point, particularly in resource-constrained settings.”
Brian Firth, CEO of Gemina, added: “I’m delighted to be seeing such significant results so quickly from our partnership with ReadyGo Diagnostics. Our goal is to create better diagnostic tests for managing patients with tuberculosis, the fact that we have proven feasibility of detecting TB in saliva opens the door to a fundamental improvement in human health and a significant contribution to eradicating TB worldwide.”
ReadyGo Diagnostics Ltd. and Gemina Laboratories Ltd. have announced a major breakthrough in their collaboration, demonstrating the successful feasibility of utilising saliva as sample for the detection of Mycobacterium tuberculosis (MTB) through a molecular diagnostic test.
The partnership, initiated in January 2023, is aiming to create a saliva-based test for MTB, which could have a profound impact on the eradication efforts of TB, particularly in countries
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.